There is no clinically validated human dose you can look up here, because for this compound one does not exist in the way regulated drugs have. We report what research and regulators actually say, and nothing more.
What it is
PT-141 is the research name for bremelanotide, a melanocortin-receptor agonist. Unlike most peptides discussed online, its active drug is FDA-approved, marketed as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
The evidence, stated plainly
The approved indication is backed by controlled trials that led to FDA approval. Uses beyond that label (for example in men, or for general libido) are off-label or unstudied, and gray-market "PT-141" is not the same as the approved product.
Approved by the FDA; a real label and dosing exist. We label evidence by its strongest honest tier, never by a vendor’s enthusiasm.
Half-life & timing
The approved drug has a characterized half-life of roughly 2.7 hours and a defined on-demand dosing scheme in its label.
Regulatory status
The active drug (bremelanotide) is FDA-approved and prescription-only for a specific indication. Research-chemical "PT-141" sold online is unregulated and not the approved product.
Storage & handling
Follow the approved product label for the pen; research powder follows standard peptide handling.
Whatever dose a protocol or provider gave you, converting it to syringe units is where errors turn into 10× mistakes. Our calculator does only that conversion — it never invents the dose.
Open the reconstitution calculatorThe honest bottom line
This is a case where an approved drug and a research chemical share a name. The approved version has a narrow, evidenced indication and a prescriber; the online version is neither. Do not treat them as interchangeable.
Sources
- FDA approval of bremelanotide (Vyleesi) for HSDD.
- Bremelanotide pharmacology (half-life ~2.7 h).
- Label indication and on-demand dosing.
Sourcing reflects literature available at publication and may change. See How We Rate Evidence.